News

Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...
40% Upside For Merck Stock?
MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.
STAT22h
Pharmalittle: We’re reading about the gray market for obesity meds, an RSV drug recommendation, and more
Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...
PharmExec18h
ACIP Recommends Merck’s Enflonsia to Prevent Respiratory Syncytial Virus in Infants
The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.
PMLive12d
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer
Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...
GEN - Genetic Engineering and Biotechnology News2d
Solution Building: Merck Avoids One-Size-Fits-All Approach to AI and ML
Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...
BioSpace2d
Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...